Peptides inhibiting heparanase procoagulant activity significantly reduce tumour growth and vascularisation in a mouse model

Thrombosis and Haemostasis

Volumn 116, Issue 4, 2016, Pages 669-678

  Crispel, Yonatan ^a   Axelman, Elena ^a   Tatour, Mifleh ^a   Kogan, Inna ^a   Nevo, Neta ^a   Brenner, Benjamin ^a   Nadir, Yona ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Heparanase; Inhibitory peptides; Tissue factor; Tumour

Indexed keywords

HEPARANASE; PEPTIDE; PROCOAGULANT; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; BETA GLUCURONIDASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; EXPERIMENTAL MELANOMA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; CELL LINE, TUMOR; GLUCURONIDASE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; THROMBOPLASTIN;

EID: 84989196026     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-02-0119     Document Type: Article

References (20)

1. Freeman C, Parish CR. Human platelet heparanase: purification, characterisation and catalytic activity. Biochem J 1998; 330: 1341–1350.
2. Pikas DS, Li JP, Vlodavsky I, et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770–18777.
3. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99–108.
4. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341–347.
5. Gingis-Velitski S, Zetser A, Flugelman MY, et al. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004; 279: 23536–23541.
6. Doviner V, Maly B, Kaplan V, et al. Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 2006; 19: 878–888.
7. Zetser A, Bashenko Y, Miao HQ, et al. Heparanase affects adhesive and tumourigenic potential of human glioma cells. Cancer Res 2003; 63: 7733–7741.
8. Cohen-Kaplan V, Naroditsky I, Zetser A, et al. Heparanase induces VEGF C and facilitates tumour lymphangiogenesis. Int J Cancer 2008; 123: 2566–2573.
9. Nadir Y, Brenner B, Zetser A, et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 4: 2443–2451.
10. Nadir Y, Brenner B, Gingis-Velitski S, et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumour cells. Thromb Haemost 2008; 99: 133–141.
11. Nadir Y, Brenner B, Fux L, et al. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haema-tologica 2010; 95: 1927–1934.
12. Axelman E, Henig I, Crispel Y, et al. Novel peptides that inhibit heparanase activation of the coagulation system. Thromb Haemost 2014; 112: 466–477.
13. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249–2258.
14. Nadir Y, Kenig Y, Drugan A, et al. An assay to evaluate heparanase procoagulant activity. Thromb Res 2011; 128: e3–8.
15. Hammond E, Li CP, Ferro V. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening. Anal Biochem 2010; 396: 112–116.
16. McKenzie E, Young K, Hircock M, et al. Biochemical characterisation of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 2003; 373: 423–435.
17. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93–105.
18. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130–2135.
19. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123–2129.
20. Nadir Y, Sarig G, Axelman E, et al. Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients. Thromb Res 2014; 134: 639–642.